|
Oct 17
|
Medidata Announces Rave Lite to Support Growth in Early and Late-Stage Clinical Trials
|
|
Oct 15
|
BioNJ & Medidata Collaborate to Address Underrepresentation in Clinical Trials Across New Jersey
|
|
Sep 5
|
Dassault Systèmes: declaration of the number of outstanding shares and voting rights as of August 31, 2024
|
|
Sep 3
|
Medidata and Aixial Group partner to streamline clinical trial execution
|
|
Sep 3
|
Aixial Group Migrates Specific Clinical Data Portfolio Onto Medidata Platform to Create a Single Source of Truth and Accelerate Database Lock
|
|
Jul 26
|
Eisai adopts Medidata’s AI-driven platform for clinical trials
|
|
Jul 26
|
Eisai Selects Medidata’s Clinical Data Studio to Enhance and Modernize Clinical Trial Efficiency and Patient Experience
|
|
Jul 25
|
Dassault Systèmes: Availability of the 2024 Half-year Financial Report
|
|
Jul 25
|
ASICS and Dassault Systèmes Demonstrate On-Demand, Personalized Footwear
|
|
Jul 25
|
Dassault Systèmes: Second Quarter 2024 Results in Line With Preliminary Announcement - Non-IFRS Diluted EPS up 10% in the First Half
|
|
Jul 25
|
Dassault Systèmes: Eisai Selects Medidata’s Clinical Data Studio to Enhance and Modernize Clinical Trial Efficiency and Patient Experience
|
|
Jun 19
|
Medidata introduces new AI-powered platform for clinical trials
|
|
Jun 18
|
Medidata Launches Clinical Data Studio, Leveraging AI to Modernize the Data Experience in Clinical Trials
|
|
Apr 9
|
Dassault Systèmes: declaration of the number of outstanding shares and voting rights as of March 31, 2024
|
|
Feb 1
|
Dassault Systèmes Doubles EPS as Planned in 2018 While Embracing The Subscription Model
|
|
Feb 1
|
BMW Group Partners with Dassault Systèmes to Bring the 3DEXPERIENCE Platform to Its Future Engineering Platform
|
|
Jan 31
|
Dassault Systemes SA (DASTY) is a Great Momentum Stock: Should You Buy?
|
|
Jan 17
|
Synopsys (SNPS) Surges 3.1%: Is This an Indication of Further Gains?
|
|
Aug 7
|
Dassault Systèmes: disclosure of trading in own shares
|
|
Apr 26
|
Dassault Systèmes: Solid First Quarter Driven by Strong Subscription, Reaffirming FY23 Objectives
|